A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|February 1, 2003
- Volume 0 0
Antidepressant Use During Pregnancy Does Not Affect Child Development
Advertisement
Use of antidepressants during pregnancy does not affect child development, according to a prospective study published in the American Journal of Psychiatry.
Researchers compared mother?child pairs who were exposed to tricyclic antidepres-sants (n = 46) or fluoxetine (n = 40) during gestation with an unexposed, nonde-pressed control group (n = 36). Neither tricyclic antidepressants nor fluoxetine affected the child?s global IQ, language development, or behavior.
Instead, the mothers? depression was associated with impaired cognitive and language achievement among their children.
Articles in this issue
over 23 years ago
Calcium and Vitamin D Prevent Tooth Lossover 23 years ago
Soy May Not Increase Bone Mineral Density in Young Womenover 23 years ago
Hormone Therapy, Antioxidants Do Not Protect Against Heart Diseaseover 23 years ago
All Pregnant Women Should Be Screened for Group B Strepover 23 years ago
Cervical Cancer Screening Not Urged for Allover 23 years ago
Bacterial Vaginosis Linked to Miscarriagesover 23 years ago
Dietary Factors Linked to High Iron Storesover 23 years ago
Growth Hormone Linked to Adverse Effectsover 23 years ago
Topical b-Blockers May Affect Airways Function in Elderly PatientsAdvertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
HIV Treatment Basics: Mechanisms, 2026 Guideline Updates, and Rapid ART Start
5